Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage.

Abstract

We assessed the influence of age on warfarin dose, percentage time in target range (PTTR), and risk of major hemorrhage. Warfarin users recruited into a large prospective inception cohort study were categorized into three age groups: young (younger than 50yrs), middle aged (50-70yrs), and elderly (older than 70yrs). The influence of age on warfarin dose and PTTR was assessed using regression analysis; risk of major hemorrhage was assessed using proportional hazards analysis. Models were adjusted for demographic, clinical, and genetic factors. Two outpatient anticoagulation clinics. A total of 1498 anticoagulated patients. Warfarin dose (mg/day), PTTR, major hemorrhage. Of the 1498 patients, 22.8% were young, 44.1% were middle aged, and 33.1% were elderly. After accounting for clinical and genetic factors, compared with young warfarin users, warfarin dose requirements were 10.6% lower among the middle aged and an additional 10.6% lower for the elderly. Compared with young patients, middle-aged and elderly patients spent more time in target international normalized ratio (INR) range (p<0.0001), despite having fewer INR assessments (p<0.0001). Compared with young warfarin users, absolute risk of hemorrhage was marginally higher among the middle aged (p=0.08) and significantly higher among the elderly (p=0.016). Compared with young warfarin users, after adjustment, the relative risk of hemorrhage increased by 31% for each age category (p=0.026). In a real-world setting, despite achieving better anticoagulation control, elderly patients had a higher risk of major hemorrhagic events. As the population ages and the candidacy for oral anticoagulation increases, strategies that mitigate the elevated risk of hemorrhage need to be identified.